Valganciclovir

Restricted
Restricted

C. diff Risk

None

Oral Bioavailability

NA

Approximate Cost

Dosing

Prophylaxis/maintenance dose: 900 mg PO q24h

Treatment/induction dose: 900 mg PO q12h

General Information

Common Usage

CMV treatment and prophylaxis

Drug Monitoring

CBC-differential and renal function periodically.

Adverse Effects

-May cause blood dyscrasias: granulocytopenia, anemia, thrombocytopenia, and aplastic anemia.
-Acute kidney injury